Plain-English translation of NCT05695313 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a dietary supplement called OnLife can prevent a common side effect of weekly paclitaxel chemotherapy — nerve damage that causes tingling, numbness, and weakness in the hands and feet. Half of the participants will receive OnLife alongside their regular chemotherapy, while the other half will receive a placebo (inactive pill) to see if the supplement actually makes a difference.
Many breast cancer patients receiving this chemotherapy develop painful nerve damage that can be severe enough to stop treatment early or reduce doses, which may affect how well the cancer is controlled. This trial is testing whether this supplement can protect nerves and allow patients to complete their full treatment plan while maintaining a better quality of life.
You would take either OnLife or placebo tablets starting a few days before your first chemotherapy dose and continue for one month after your final dose (about 13–14 weeks total). You would receive your regular weekly chemotherapy as usual, attend follow-up appointments to monitor how you're doing, and complete questionnaires about any nerve symptoms or side effects you experience. The study compares the two groups to see if the supplement reduces nerve damage compared to placebo.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
France